|
The Centre d’Immunologie de Marseille-Luminy (CIML) was founded in 1976 and has been described by AERES, an independent evaluation agency, as "without doubt one of the best immunology centers of excellence in Europe".〔(【引用サイトリンク】title=AERES 2011 report on the CIML )〕 The CIML addresses all areas of contemporary immunology; it is located in Marseille in the South of France. == Function == The institute has 17 research teams, with 250 staff including 185 scientists, students, and post-docs from 24 countries. It offers Masters and PhD programs. The CIML has 90 academic collaborations and 21 industrial partners in France, Europe, and worldwide, and has formed several spin-offs, including: Innate Pharma, Ipsogen (Quiagen), and Immunotech (Beckman-Coulter). The institute has published over 400 scientific publications in the last 5 years, including 145 in journals with an impact factor ≥ 10.〔(【引用サイトリンク】title=Web of Knowledge - IP & Science - Thomson Reuters )〕 It is located on a science campus that is home to more than 1,500 researchers and 10,000 students, and 15 biotech companies. 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Centre d'immunologie de Marseille-Luminy」の詳細全文を読む スポンサード リンク
|